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ABSTRACT 
High-bone-mass (HBM)-causing missense mutations in the low density lipoprotein receptor-related protein-5 (Lrp5) are 
associated with increased osteoanabolic action and protection from disuse- and ovariectomy-induced osteopenia.  These 
mutations (e.g., A214V and G171V) confer resistance to endogenous secreted Lrp5/6 inhibitors, such as sclerostin 
(SOST) and Dickkopf homolog-1 (DKK1).  Cells in the osteoblast lineage are responsive to canonical Wnt stimulation, 
but recent work has indicated that osteoclasts exhibit both indirect and direct responsiveness to canonical Wnt.  Whether 
Lrp5-HBM receptors, expressed in osteoclasts, might alter osteoclast differentiation, activity, and consequent net bone 
balance in the skeleton, is not known.  To address this, we bred mice harboring heterozygous Lrp5 HBM-causing 
conditional knock-in alleles to Ctsk-Cre transgenic mice and studied the phenotype using DXA, µCT, histomorphometry, 
serum assays, and primary cell culture.  Mice with HBM alleles induced in Ctsk-expressing cells (TG) exhibited higher 
bone mass and architectural properties compared to non-transgenic (NTG) counterparts.  In vivo and in vitro 
measurements of osteoclast activity, population density, and differentiation yielded significant reductions in osteoclast-
related parameters in female but not male TG mice.  Droplet digital PCR performed on osteocyte enriched cortical bone 
tubes from TG and NTG mice revealed that ~8-17% of the osteocyte population (depending on sex) underwent 
recombination of the conditional Lrp5 allele in the presence of Ctsk-Cre.  Further, bone formation parameters in the 
midshaft femur cortex shows a small but significant increase in anabolic action on the endocortical but not periosteal 
surface.   These findings suggest that Wnt/Lrp5 signaling in osteoclasts affects osteoclastogenesis and activity in female 
mice, but also that some of the changes in bone mass in TG mice might be due to Cre expression in the osteocyte 
population.   
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INTRODUCTION 
 Most FDA-approved therapies for osteoporosis target the bone-resorbing activities of osteoclasts(1).  More 
recently, anabolic treatments have been considered a promising approach to improve bone properties.  Approved agents 
that stimulate anabolic action are focused around the PTH/PTHrP axis, but discoveries regarding anabolic potential of the 
Wnt signaling pathway have provided other avenues to achieve anabolism in bone (2, 3).  Several plasma membrane 
receptors are involved in the Wnt signaling pathway, including the low density lipoprotein receptor-related protein-5 
(LRP5).  Numerous reports indicate that LRP5 is a key protein involved in the regulation of bone mass (4).  The 
importance of LRP5 in skeletal regulation has been addressed using genetically engineered mouse models, all of which 
consistently show significant changes in bone mass and strength with gain- and loss-of function mutations in the gene (5-
9).  
 Much of the high bone mass (HBM) phenotype described in mice with LRP5 HBM-causing mutations (e.g. Lrp5-
HBM transgene or knock-in point mutations) has been ascribed to altered anabolic signaling in the osteoblast/osteocyte.  
Mice with HBM-causing missense mutations in Lrp5 provide robust gain-of-function models because LRP5 HBM 
receptors respond normally to Wnt ligands but exhibit resistance to endogenous inhibitors such as sclerostin (SOST) and 
Dickkopf homolog-1 (DKK1) (10-13).  Additionally, these mutations enhance responsiveness to mechanical loading and 
protect the skeleton from the bone-wasting effects of mechanical disuse (14, 15).   
 While most of the published reports on Wnt action in bone have focused on the anabolic effects in osteoblasts, or 
on the anabolism-relaying effects in osteocytes, much less is known about Wnt signaling in osteoclasts.   Osteoclasts are 
modulated by Wnt proteins, secreted by neighboring osteoblasts and osteocytes (16).  Beyond indirect effects on the 
osteoclast (e.g., Wnt-modulated RANKL/OPG production by osteocytes/osteoblasts), more recent data suggest that Wnt 
stimulation can have direct effects on osteoclasts (17).  The most thoroughly characterized mechanism for direct 
osteoclast stimulation by Wnt is the Wnt5a/Ror2 pathway, which activates one of the non-canonical arms of intracellular 
Wnt signaling (18).  However, osteoclasts also express the molecular machinery to transduce canonical Wnt signaling 
(e.g., LRP5/6, FZDs, β-catenin, GSK3β) (19), and deletion of LRP5/6 in early osteoclasts results in increased resorption 
and low bone mass, whereas treatment of osteoclast cultures with the canonical ligand Wnt3a induces β-catenin nuclear 
translocation and suppresses osteoclast differentiation (17).  In light of the accumulating evidence that canonical Wnt 
signaling might have a significant role in the osteoclast, we hypothesized that osteoclast-selective (i.e., Ctsk-Cre-
mediated) expression of LRP5 receptors harboring the HBM-causing G171V or A214V mutations would exhibit 
increased bone mass via Wnt-mediated inhibition of osteoclasts.   
 In this communication, we sought to investigate whether expression of LRP5 gain-of-function mutations (G171V, 
A214V) in osteoclasts would alter bone homeostasis in vivo and osteoclastogenesis in vitro.  Mice harboring heterozygous 
Lrp5 HBM-causing conditional knock-in alleles were bred with Ctsk-Cre transgenic mice.  We evaluated in vivo actions 
of both Lrp5 mutant alleles individually, expressed in osteoclasts, on bone mass and degradation.  We also explored the in 
vitro effects of the mutations on osteoclast differentiation and activity, using bone marrow hematopoietic stem cells 
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isolated from the mutant mice.  Here, we report that Lrp5 HBM-causing knock-in alleles in Ctsk-expressing cells 
significantly increase overall bone mass and reduce resorption in female mice, but have more mild effects in male mice.    
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MATERIALS AND METHODS 
Experimental Mice 
 Mice with Lrp5 conditional knockin alleles for HBM-causing mutations A214V and G171V have been described 
previously (5).  These alleles, Lrp5AN and Lrp5GN, respectively) are activated by Cre-recombination.  Male mice with 
conditional Lrp5 alleles were crossed to hemizygous female Ctsk-Cre transgenic (TG) mice, which is expressed in 
osteoclasts (20). Offspring with the following genotypes were studied TG;+/A (mice with the Lrp5AN allele and the Ctsk-
Cre transgene), NTG;+/A (mice with the Lrp5AN allele but not the Ctsk-Cre transgene), TG;+/G (mice with Lrp5GN allele 
and the Ctsk-Cre transgene), and NTG;+/G (mice with the Lrp5GN allele but not the Ctsk-Cre transgene).  The genetic 
background of all mice was a mixture of 129S1/SvIMJ and C57Bl/6J.  Offspring were same sex–housed in cages of 3 to 5 
(independent of Ctsk-Cre genotype) and given standard mouse chow [Harlan Teklad 2018SX; 1% Ca; 0.65% P; vitamin 
D3 (2.1 IU/g)] and water ad libitum. The Lrp5 alleles and the Ctsk –Cre transgene were genotyped using standard PCR on 
genomic DNA from ear notches.  All animal procedures were performed in accordance with relevant federal guidelines 
and conformed to the Guide for the Care and Use of Laboratory Animals (8th Edition).  The animal facility at Indiana 
University is an AAALAC-accredited facility.    
Dual-energy x-ray absorptiometry (DEXA) 
 Whole-body DEXA scans were collected on isoflurane-anesthetized mice using a PIXImus II (GE Lunar, 
Madison, WI) densitometer.  All experimental mice were scanned at 7, 10, and 15 weeks of age as indicated in Fig 1A.  
From the whole body scans, areal bone mineral density (BMD) and bone mineral content (BMC) were calculated for the 
entire postcranial skeleton using the Lunar ROI tools.   
Micro-computed tomography (µCT) 
 The right femur was extracted at sacrifice (16 weeks of age) and fixed in 4% PBF for 2 days, then transferred into 
70% ethanol.  A 2.6-mm span of the distal femoral metaphysis was scanned on a desktop µCT (µCT 20; Scanco Medical 
AG) at 13-µm resolution using 70-kV peak tube potential and 151-ms integration time to measure trabecular three-
dimensional morphometric properties as previously described (21).  Standard trabecular bone parameters (BV/TV, Tb.N, 
Tb.Th) were calculated from each reconstructed stack through the metaphysis.  Cortical thickness (Ct. Th) and area 
(Ct.Ar) were obtained from 20 slices reconstructed through the midshaft femur at 9-µm resolution.    
Measurements of serum bone resorption markers and osteoclast enumeration in mice 
 To measure levels of the serum resorption marker carboxy-terminal collagen cross-links (CTx), blood samples 
were collected from each mouse at 7 weeks of age, allowed to clot for 30 to 60 minutes, and then centrifuged to separate 
and collect serum.  CTx was measured from the serum using a commercially available plate assay (IDS Ratlaps EIA, 
Gaithersburg, MD) following the manufacturer’s instructions.  Serum samples from 10 mice per group were analyzed.  
Additionally, after conducting µCT measurements on the right femur, we processed those tissues for plastic-embedded 
thin sectioning and Trap-staining as described previously (22).  Osteoclast number per unit bone surface (Oc.N/BS, #/mm) 
and osteoclast surface per unit bone surface (Oc.S/BS, %) were measured in metaphyseal cancellous bone.    
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Osteoclast culture and osteoclastogenic assays 
 Bone marrow-derived macrophages (BMMs) were prepared as previously described (23).  Briefly, bone marrow 
was isolated from 6-week old mice heterozygous for the Lrp5 G171V conditional allele (G171V), with or without the 
Ctsk-Cre transgene.  After culturing for 24 h in α-MEM containing 10% FBS, non-adherent cells were collected and 
cultured in α-MEM containing 10% FBS with M-CSF and RANKL (PeproTech, NJ, USA) For osteoclastogenesis assays, 
cells were plated at 6104 cells/well in a 96 well plate and cultured for 4-5 days until the appearance of multinucleated 
osteoclasts.  The osteoclasts were then fixed in 4% paraformaldehyde for 10 min and then stained for TRAP with 0.1 M 
acetate solution (pH 5.0) containing 6.7 mM sodium tartrate, 0.12 mg/ml naphthol AS-MX phosphate, and 0.07 mg/ml 
fast red violet.  After TRAP staining, the numbers of red-stained TRAP-positive cells that had more than three nuclei and 
a red cytosol were counted under a light microscope.  The average was calculated from 5 wells of 96-well plates.  This 
counting was repeated five times.  To determine the bone resorption activity of osteoclasts, multinucleated osteoclasts 
cultured in the presence of RANKL and M-CSF for 4-5 days were treated with 0.025% trypsin-EDTA for 3-5 min (with 
light mechanical scraping) to release the cells.  The detached mature osteoclasts were washed in growth media, and an 
identical number of cells were reseeded onto sterilized cortical bone slices (approx. 200 osteoclasts per slice in 96 well 
plates; IDS, Ltd, Boldon, UK). After 3 days of culture on bone slices, the conditioned media was collected for 
biochemical evaluation of osteoclast resorption activity (CTx ELISA, IDS Inc., Gaithersburg, MD).  The bone slices were 
TRAP stained for osteoclast enumeration, and the osteoclast counts were used to normalize the CTx data (CTx/OC 
number).  To stain osteoclast resorption pits, the TRAP-stained cells on bone slices were first removed using mechanical 
agitation, and the slices were incubated with 20 μg/ml of peroxidase-conjugated wheat germ agglutinin for 45 min, 
followed by the staining of the pits with chromogen 3,3′-diaminobenzidine (Sigma-Aldrich, St Louis, MO). To quantify 
the resorption on each bone slice, the resorbed pits were identified and measured for area using ImageJ.    
Gene expression of osteoclast-selective transcripts using quantitative PCR 
Non-adherent bone marrow cells were prepared as described above and cultured with M-CSF alone to form macrophages 
(50 ng/ml M-CSF for 3 days) or with M-CSF plus RANKL to form pre-osteoclasts (20 ng/ml M-CSF plus 80 ng/ml 
RANKL for 3 days) and mature osteoclasts (20 ng/ml M-CSF plus 80 ng/ml RANKL for 5 days). The formation of pre-
osteoclasts and mature osteoclasts was confirmed based on their morphology. RNA was isolated from the cell 
preparations using Qiagen RNeasy kits, and the cDNAs were synthesized from 1 μg of RNA using SuperScript synthesis 
system (Invitrogen). Quantitative RT-PCR was performed on an ABI 7900HT Real time PCR system (Applied 
Biosystems) using SYBR Green PCR Master Mix assay (Applied Biosystems) for the following transcripts: Oscar, 
Dcstamp, Ctsk, Clcn7, and Atp6ap1.  Primer sequences are listed in Table S1.  The amplification reaction was performed 
for 40 cycles with denaturation at 95°C for 10 minutes, followed by annealing at 95°C for 15 seconds and extension and 
detection at 60°C for 1 minute. Gene expression was quantitated using the 2−ΔΔCT method and normalized to transcripts for 
the housekeeper GAPDH.  
Droplet digital PCR assay for genomic recombination of the conditional Lrp5-HBM alleles 
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Droplet digital PCR (ddPCR) was performed as previously described (24).  Briefly, epiphyseal ends of bone were 
removed from cleaned long bones and the bone marrow removed by extensive washing with PBS.  DNA was extracted 
from bone pieces using the DNeasy Blood and Tissue Kit (Qiagen) and ~ 3 ng of cortical bone DNA was used in 
subsequent PCR reactions.  Supermix for Probes mastermix (BioRad, Hercules, CA) was used following the 
manufacturer’s recommendations.  PCR was performed using Eppendorf EP gradient S machines, nanodroplets were 
created using an automatic droplet generator, amplimer containing droplets were counted with a QX200 sample reader, 
and data were analyzed using Quantasoft software (all instrumentation from BioRad). The primer pairs and probes 
described below were purchased from IDT (Coralville, IA) and were used to amplify and quantify the number conditional 
and recombined alleles.  At least 200 amplimer-containing droplets per animal were created in order to measure Cre-
mediated recombination.  PCR primers, P26-AGTACTGGCTGGCACAGA, P27-CAGGCTGCCCTTGCAGAT, and 
P28-GTCAGTTTCATAGCCTGA were combined and used in a single PCR reaction to generate a 320-bp amplimer for 
the conditional allele and a 400-bp amplimer for the recombined allele.  The conditional allele was detected using a 
5HEX/CCGCAAGCTCTAGAGTCAGCTTCTGAT/3IABkFQ probe, while the recombined allele was detected using a 
56-FAM/CGGAATTTAGAGGATCCCCGGGTACC/3IABkFQ probe. PCR parameters were run as follows: 95°C for 10 
minutes; 94°C for 30 seconds, 57°C for 60 seconds, 72C for 30 seconds, for 40 cycles at 20% ramp; 98°C for 10 minutes, 
and then 12°C indefinitely. 
Quantitative histomorphometry 
 Demeclocycline (60 mg/kg IP) and calcein (12 mg/kg IP) were injected at 7 and 15 weeks of age, respectively.  
After collecting left femurs at sacrifice (17 weeks of age), the 4% PBF-fixed femurs were dehydrated in graded ethanols, 
cleared in xylene, and embedded in methylmethacrylate (MMA).  Thick sections were cut from the midshaft using a 
diamond-embedded wafering saw.  Sections were ground and polished to ~30 µm, mounted and coverslipped, then 
digitally imaged on a fluorescent microscope.  Periosteal and endocortical bone formation parameters were calculated by 
measuring the extent of unlabeled perimeter (nL.Pm), single-labeled perimeter (sL.Pm), double-labeled perimeter 
(dL.Pm), and the area between the double labeling with Image-Pro software (MediaCybernetics Inc., Gaithersburg, MD).  
The derived histomorphometric parameters mineralizing surface over bone surface (MS/BS), mineral apposition rate 
(MAR), and bone formation rate (BFR/BS) were calculated using standard procedures described elsewhere (25).   
Statistical methods 
 Statistical analyses were computed using two-way ANOVA, with Ctsk-Cre genotype, TG(transgenic) or non- 
NTG (non-transgenic), and Lrp5 genotype,  +/A or +/G, as main effects.  Significant main effects were followed up with 
all-pairwise post-hoc comparisons using Fishers protected LSD tests.  Significance was taken at p < 0.05.  All data are 
presented as mean ± SEM. 
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RESULTS 
Increased bone mass in mice with activated Lrp5 HBM alleles in Ctsk-Cre expressing cells.  
     To determine changes in bone mineral content and density among mice with Ctsk-Cre-driven activation of Lrp5 HBM 
alleles, we collected serial whole body DEXA scans from all experimental mice (Fig 1).  Ctsk-Cre TG mice with either 
Lrp5 HBM allele had increased BMD (5-7% in female, 9-12% in male) and BMC (7-13% in female, 12-15% in male) 
compared to NTG mice, regardless of sex (Fig 1).  There was no difference in BMC and BMD in male TG mice with the 
+/A or +/G allele, whereas female TG;+/A mice had significantly higher BMC and BMD than TG;+/G mice (Fig 1).  
     Analysis of the distal femur by µCT indicated that male and female TG;+/A and TG;+/G mice had significantly higher 
trabecular BV/TV, cortical thickness, and cortical area than their NTG littermates (Fig 2).   Vertebral bone mass did not 
differ between NTG and TG mice for either sex (Fig. S1).   
Serum markers of bone resorption and histological measures of osteoclast prevalence are reduced in female but not 
male mice with Lrp5 mutations induced in Ctsk-Cre-expressing cells  
     To evaluate osteoclastic activity in these mice, we measured CTx concentration from serum collected at week 7, and 
we measured the number of, and surface occupied by, osteoclasts in the distal femur metaphysis after sacrifice (Fig 3).  
Female TG;+/A and TG;+/V mice had reduced serum CTx concentrations (by 10-13%) compared to their NTG 
littermates, whereas CTx concentrations did not differ in male TG versus NTG mice.  Histomorphometric measurements 
of osteoclast parameters in 16 wk old mice were consistent with the serum CTx concentration results; female TG;+/A and 
TG;+/G mice had significantly fewer osteoclasts in the distal femur, reaching a 13-16% decrease in OCL surface and a 
32-70% reduction in OCL number, compared to their respective NTG littermates.  We did not detect any significant 
differences in osteoclast histological parameters among male mice.  
Osteoclast differentiation and activity are reduced in marrow cultures derived from female and not male TG;+/G mice 
     To determine whether changes in osteoclast-associated measures seen in vivo reflect cell autonomous effects of the 
active Lrp5 allele, we studied osteoclast differentiation and function in vitro. Bone marrow-derived hematopoietic stem 
cells from +/G mice, with or without the Ctsk-Cre transgene, were used as a source of OC progenitors, and were induced 
to differentiate using M-CSF and RANKL.  Consistent with what was observed in vivo, TRAP staining indicated 45% 
fewer OCs differentiated in vitro from bone marrow progenitors recovered female TG;+/G compared to NTG;+/G mice.  
Also consistent with the sex specific in vivo data, no difference in in vitro OC differentiation was observed between male 
TG;+/G and NTG mice (Fig 4A-4B).  The observed sex-related difference in osteoclast formation was not due to initial 
seeding density, as the same outcome was observed over three different seeding densities (Fig. S1).  Additionally, to 
measure bone resorbing activity of osteoclasts, we re-plated identical numbers of osteoclast-like cells onto bovine cortical 
bone slices and measured the resorbed (“pit”) area after staining.  Bone slices containing TG;+/G osteoclasts from female 
mice had 60% lower pit area than NTG littermate females, while male-derived preparations showed no detectable 
difference between groups (Fig 4C-4D).  Removal of osteoclasts for re-plating onto the bone slices was not associated 
with a significant loss of, or damage to, cells from female or male mice (Fig. S3).  The amount of CTx released into the 
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culture media was also suppressed in female but not male TG mice (Fig. 4E).  Expression of osteoclast-selective genes 
was reduced in female but not male transgenic mice, compared to respective NTG controls (Fig. 5).  
The Ctsk-Cre transgene recombines conditional Lrp5-HBM alleles in bone cells other than osteoclasts, with greater 
“off-target” recombination occurring in females rather than males. 
     Although Ctsk-Cre is commonly used to induce Cre-mediated recombination in osteoclasts, it may also be active in 
other skeletal cell types.  These “off-target” effects could contribute to the increased bone mass observed in TG;+/A and 
TG;+/G mice.  Because osteocytes express Ctsk, particularly under resorption-inducing conditions (26), and since we 
previously reported that activation of conditional HBM alleles in osteocytes was sufficient to increase bone mass (5), we 
determined whether the Ctsk-Cre transgene was active in cortical bone which is enriched for osteocytes.  We extracted 
DNA from femoral cortical bone of TG;+/G and NTG mice and used ddPCR to measure the percentage of Lrp5 
conditional alleles in this tissue that had recombined.  The rate of recombination in NTG mice did not exceed the 
background level for this assay (<1%).  In contrast, male TG;+/G mice had ~8% of their cortical bone Lrp5 alleles 
recombined; the rate of cortical bone Lrp5 recombination in female TG;+/G mice was even higher (Fig. 6).  
     In addition to observing off-target expression in osteocytes, we also noted that the Ctsk-Cre TG is active during male 
gametogenesis.  If a sire has the Ctsk-Cre TG and a floxed allele, the allele will be inherited recombined in the offspring.  
This is why all animals in this study inherited the floxed allele from the sire and the Ctsk-Cre TG from the dam.  
  
Midshaft femur bone formation parameters are increased on the endocortical but not periosteal surface in mice with 
Lrp5-HBM mutations induced in Ctsk-Cre-expressing cells 
     Having found evidence for Ctsk-Cre induced Lrp5 HBM activation in osteocytes, we performed dynamic 
histomorphometry to assess whether some of the increased bone mass in TG;+/A and TG;+/G mice might be due to 
increased bone formation.  Endocortical bone formation (MS/BS and BRF/BS) was significantly increased in male and 
female TG;+/A mice compared to NTG controls and increased in male, but not female, TG;+/G mice compared to 
controls (Fig 7).  Presence of the TG had no effect on periosteal bone formation.  
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DISCUSSION 
     The importance LRP5 signaling to bone anabolism is well known. Mice with global Lrp5 HBM mutations and mice 
with conditional activation of the Lrp5 HBM allele in osteocytes/osteoblasts, had significantly increased bone formation 
compared to controls (5, 14). Transgenic mice overexpressing a human LRP5 G171V cDNA in osteoblasts (2.3kbCol1α1–
Lrp5.G171V) also had significantly increased bone formation (15, 27).   LRP5 also appears to have a role in preventing 
bone catabolism.  We reported that Lrp5 HBM mice were protected from the bone catabolic effects of disuse and estrogen 
deficiency (OVX) (14).  Unknown, was whether the HBM mice were protected from catabolism because of anti-
osteoclastogenic signals that originated from osteocytes/osteoblasts, from a cell-autonomous role for LRP5 during 
osteoclast differentiation/function, or both.  Experiments in the present communication were designed to address a cell-
autonomous role for LRP5 in osteoclasts.   
   We observed that Ctsk-Cre-driven recombination of conditional Lrp5 HBM alleles led to increased bone mass and 
architectural properties in male and female mice (Figs 1 and 2), which could be due to increased anabolism or decreased 
catabolism.  In vivo evidence of decreased catabolism was observed in female, but not male, mice (Fig 3).  Since 
osteocytes/osteoblasts help regulate osteoclast activity by expressing RANKL and OPG, we performed in vitro osteoclast 
differentiation and activity assays to determine if the LRP5 effects were cell autonomous.  We observed significant 
reductions in the number of osteoclasts that could be differentiated bone marrow precursors in vitro from in female (Fig 
4), but not male, TG;+/G mice, and decreased resorptive ability of isolated TG;+/G osteoclasts ex vivo (Figs 4 and 5).  
Taken together, these data are consistent with LRP5 having a cell-autonomous role in osteoclast function; this role 
appears sex-specific.    
    Because bone mass was increased in male TG;+/A and TG;+/G mice, despite there being no apparent effect on 
osteoclast differentiation or resorption, we sought another reason these mice developed increased bone mass.  We looked 
for “off target” recombination of the Lrp5 HBM allele in osteocytes, for which pro-anabolic roles of LRP5 are known.  
Osteocytes express Ctsk, albeit at much lower levels than osteoclasts (26).  We therefore asked whether Ctsk-Cre is also 
expressed in osteocytes.  Droplet digital PCR indicated that Ctsk-Cre was active in ~ 8 to 17% of osteocytes, with females 
having greater rates of cortical bone recombination than mice.  This low, but appreciable, percentage of recombined cells 
could account for the 2 to 4% increased bone volume fraction and the elevated endocortical bone formation rate seen in 
TG;+/A and TG;+/G mice (Fig 7).  Puzzling, however, is that only endocortical bone formation increased, since global 
HBM and osteocyte/osteoblast specific activation of HBM alleles increased endocortical and perisosteal bone formation 
(5).  Therefore, we cannot preclude the possibility that increased endocortical bone formation in Ctsk-Cre TG mice is the 
consequence of recombined osteoclasts releasing pro-anabolic coupling factors that affect osteoblasts.  The results we 
obtained using Ctsk-Cre to activate Lrp5 HBM alleles are not inconsistent with the results obtained by Weivoda et al (17), 
who used Ctsk-Cre to inactivate Lrp5; they found no effect on bone mass.  However, these investigators did show that 
bone mass was reduced when Lrp5 was inactivated using a different and earlier-acting osteoclast Cre driver (Rank-Cre) 
(17).   
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     In conclusion, our results support the hypothesis that there is a cell-autonomous role for LRP5 in osteoclasts.  In 
female mice, Ctsk-Cre mediated activation of Lrp5 HBM alleles reduced osteoclast differentiation and bone resorbing 
activity in vivo and in vitro.  Ctsk-Cre mediated activation of Lrp5 HBM alleles also significantly increased bone mass in 
male mice, however the mechanism is less certain.  It is possible that osteoclasts with active Lrps5 HBM alleles released 
pro-anabolic factors that affected osteoblasts.  Alternatively, “off target” Ctsk-Cre activity in a small percentage of 
osteocytes may have been sufficient to promote increased endocortical bone formation.   Additional experiments are 
needed to address these two possibilities.   
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FIGURE LEGENDS 
Fig 1. Increased bone DEXA values in mice with activated Lrp5 HBM alleles in Ctsk-Cre expressing cells.  (A) 
Schematic diagram of the experimental design.  (B - E) Skeletal mass and density were increased significantly in Lrp5 
HBM conditional mice (+/A or +/G) when the Ctsk-Cre transgene was present (TG, open symbols) compared to  non-
transgenic mice (NTG, filled symbols).   Whole body bone mineral content (WB BMC) and density (WB BMC) were 
measured by DXA at 7, 10, and 15 weeks using an ROI that encompassed the entire postcranial skeleton of (B and C) 
female and (D and E) male mice. * p < 0.05 compared to Lrp5-matched NTG counterpart, † p < 0.05 compared to +/G TG 
mice.  Sample size is n=11/group. 
Fig 2. Increased bone µCT values in mice with activated Lrp5 HBM alleles in Ctsk-Cre expressing cells.  (A) Trabecular 
bone volume fraction (Tb.BV/TV), (B) cortical thickness (Ct.Th), and (C) cortical area (Ct.Ar) were measured in the 
femora of 16-week-old female Lrp5 heterozygous +/A and +/G mice, with (+) or without (-) the Ctsk-Cre transgene (* p < 
0.05 compared to each NTG counterpart, + p < 0.05 compared to +/A TG mice).  (D) Representative µCT reconstructions 
of the distal femur of all female experimental groups.  (E-G) Same parameters measured in femora from 16-week-old 
male mice. (* p < 0.05 compared to each NTG counterpart, † p < 0.05 compared to +/G TG mice).  (F) Representative 
µCT reconstructions of the distal femur of all male experimental groups.  Sample size in n=11/group. 
Fig 3. Reduced bone resorption in female, but not male, mice with activated Lrp5 HBM alleles in Ctsk-Cre expressing 
cells.  The resorption marker carboxyl-terminal collagen crosslinks (CTx) was measured from serum collected from (A) 
female and (D) male Lrp5 heterozygous +/A and +/G mice, with (+) or without (-) the Ctsk-Cre transgene at 7 weeks of 
age.  Osteoclast surface per bone surface (Oc.S/BS; panels B and E) and number of osteoclast per bone surface (N.Oc/BS; 
panels C and F) were measured in the distal femoral metaphysis in sections from 16-week-old mice by counting tartrate-
resistant acid phosphatase (TRAP)-positive cells over bone surface.  * p < 0.05 compared to each Cre-negative 
counterpart, † p < 0.05 compared to +/G Cre-positive mice.  Sample size in n=11/group. 
Fig 4.  Reduced in vitro osteoclastic differentiation and bone resorption in female, but not male, mice with activated Lrp5 
HBM alleles in Ctsk-Cre expressing cells.  Photomicrographs (A) and graph (B) depicting TRAP stained OCs 
differentiated from bone marrow, Photomicrograph (C) and graph (D) depicting TRAP stained resorption pit assays, and 
(E) graph depicting. ELISA-based quantitation of C-terminal telopeptide (CTx) released into the media after 3 days of 
culture, standardized by osteoclast number (Oc.N).  * p < 0.05 compared to NTG counterpart.  Sample size in n=3/group. 
Fig. 5.   In vitro assessment of transcripts associated with osteoclastogenesis and maturity in macrophages (MQ; day 0 of 
culture from BMMs), preosteoclasts (day 2 of culture in osteoclast-differentiating conditions), and mature osteoclasts (day 
4 in osteoclast-differentiating conditions).  Quantitative PCR was used to measure expression of (A) osteoclast associated, 
immunoglobulin-like receptor (Oscar), (B) Dendrocyte expressed seven transmembrane protein (Dcstamp), (C) 
Cathepsin-K (Ctsk), (D) Chloride voltage-gated channel 7 (Clcn7), and (E) V-type proton ATPase (Atp6ap1). Expression 
levels for each gene were normalized to Gapdh expression.  * p < 0.05 compared to NTG counterpart.  Sample size in 
n=3/group. 
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Fig 6. Ctsk-Cre is active in bone cells other than osteoclasts. (A) Schematic depicting a portion of the Lrp5 HBM 
conditional alleles.  The ddPCR assay was designed distinguish non-recombined (neo-containing) and recombined (neo-
excised) alleles.  (B) Scatterplots depicting ddPCR results using cortical bone DNA from Lrp5+/+ mice (B1, which contain 
only empty droplets in the bottom left quadrant), Lrp5+/GN mice without the Ctsk-Cre TG (B2, which also contains droplets 
with non-recombined alleles [“cond”] in the right lower quadrant ), and Lrp5+/GN mice with the Ctsk-Cre TG (B3, which 
now also contains recombined alleles [“rec”] in the left upper quadrant. Graph depicting mean percentages of recombined 
alleles ( 1SD) in male +/G, male TG;+/G, and female TG;+/G mice. * p < 0.05 compared to NTG samples, † p< 0.05 
compared to the TG;+/G male samples.  Sample size is n=3/group, and each DNA sample was assayed in triplicate.   
Fig 7. Increased endocortical, but not perisosteal, bone formation in mice with activated Lrp5 HBM alleles in Ctsk-Cre 
expressing cells. Bone formation parameters were measured in the femoral midshaft from 16-week-old (A-F) female and 
(G-L) male mice by mineralizing surface per bone surface (MS/BS), mineral apposition rate (MAR), and bone formation 
rate per unit bone surface (BFR/BS).  Endocortical (A-C, G-I) and periosteal (D-F, J-L) were analyzed separately.  Both 
female and male TG mice gained new bones on endocortical region compared to each counterpart but the bone gain in 
TG;+/G female mice was not significant compared to NTG;+/G female mice. Periosteal BFR/BS in females and males 
was not statistically noticeable.  * p < 0.05 compared to each NTG counterpart.  Sample size in n=11/group. 
 
 
SUPPLEMENTARY FIGURE LEGENDS 
Fig. S1. Lrp5-HBM mutations induced in Ctsk-expressing cells resulted in similar vertebral (5th lumbar vertebra) 
trabecular bone mass compared to those without the Ctsk-Cre transgene, in both (A) female and (B) male mice.   
Fig. S2. Osteoclast formation is impaired in female but not male transgenic mice, regardless of initial seeding density.  
Three different initial seeding densities of osteoclasts were assayed for Trap staining (3104, 6104, and 9104 per well of 
a 96-well plate) after 4-5 days of culture. Regardless of the initial seeding density, the size and the number of osteoclasts 
from female TG mice were significantly lower than all other groups, although the overall number of mature osteoclasts 
(>3 nuclei) was greater with higher number of initial cells. 
Fig. S3. Osteoclasts were differentiated in 48 well culture dishes as described in the methods. Mature multinucleated cells 
were enumerated before being detached with trypsin, and then reseeded into culture wells and counted again after 6 hr.  
Approximately 85-90% of the original osteoclast number was recovered after reseeding, regardless of the sex or genotype 
of the starting culture. The number of osteoclasts from female TG mice were significantly lower than the other groups 
before and after reseeding, indicating that reseeding had no effect on the observed female-specific decrease in osteoclast 
number.   
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